Literature DB >> 19513612

RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level.

Jinghua Ren1, Wenshan He, Ruiguang Zhang, Zhenyu Li, Wenmiao Cao, Jie Yao, Fang Zhu, Tao Zhang, Gang Wu.   

Abstract

Loss of the RASSF2A expression induced by methylation-mediated silencing has been reported in several human cancers, but the methylation status of RASSF2A in hepatocellular carcinoma (HCC) is rarely studied so far. In this study, we investigated the RASSF2A expression and its methylation status in a cohort of 45 hepatitis B virus-associated HCC tissues and their adjacent non-carcinoma tissues by using RT-PCR and MS-PCR. Promoter methylation of RASSF2A was found in 31 (68.9%) out of 45 HCC tissues and 12 (40%) out of 30 adjacent normal tissues, respectively (P<0.05). The methylation status of PASSF2A was closely associated with the loss of RASSF2A expression and elevated serum alpha-fetoprotein level, but not significantly with clinical stage, hepatic fibrosis and K-ras mutation. It was concluded that aberrant methylation of the RASSF2A gene with the subsequent loss of RASSF2A expression plays an important role in the pathogenesis of HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513612     DOI: 10.1007/s11596-009-0309-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  14 in total

1.  RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor.

Authors:  Michele D Vos; Chad A Ellis; Candice Elam; Aylin S Ulku; Barbara J Taylor; Geoffrey J Clark
Journal:  J Biol Chem       Date:  2003-05-05       Impact factor: 5.157

2.  Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.

Authors:  Li-Sung Hsu; Hsin-Chen Lee; Gar-Yang Chau; Pen-Hui Yin; Chin-Wen Chi; Wing Yiu Lui
Journal:  Oncol Rep       Date:  2006-02       Impact factor: 3.906

3.  Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.

Authors:  Zhe Zhang; Di Sun; Do Nguyen Van; Anzhou Tang; Lifu Hu; Guangwu Huang
Journal:  Int J Cancer       Date:  2007-01-01       Impact factor: 7.396

4.  Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.

Authors:  Hye-Won Park; Hio Chung Kang; Il-Jin Kim; Sang-Geun Jang; Kun Kim; Hyun-Ju Yoon; Seung-Yong Jeong; Jae-Gahb Park
Journal:  Int J Cancer       Date:  2007-01-01       Impact factor: 7.396

5.  A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.

Authors:  A Hatzaki; E Razi; K Anagnostopoulou; K Iliadis; A Kodaxis; D Papaioannou; S Labropoulos; M Vasilaki; P Kosmidis; A Saetta; M Mihalatos; G Nasioulas
Journal:  Mol Cell Probes       Date:  2001-10       Impact factor: 2.365

6.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

Authors:  Shian-Yang Peng; Wei J Chen; Po-Lin Lai; Yun-Ming Jeng; Jin-Chuan Sheu; Hey-Chi Hsu
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

7.  Targeted screening of SiRNA directed HBV polymerase gene for effective inhibition of HBV expression.

Authors:  Jinjian Yao; Weiling Yu; Ying Chang; Jinghua Ren; Dong Xu; Siyuan Han; Jusheng Lin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-06-19

8.  RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer.

Authors:  M Endoh; G Tamura; T Honda; N Homma; M Terashima; S Nishizuka; T Motoyama
Journal:  Br J Cancer       Date:  2005-12-12       Impact factor: 7.640

9.  Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.

Authors:  W N Cooper; R E Dickinson; A Dallol; E V Grigorieva; T V Pavlova; L B Hesson; I Bieche; M Broggini; E R Maher; E R Zabarovsky; G J Clark; F Latif
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

10.  Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features.

Authors:  K Harada; S Hiraoka; J Kato; J Horii; H Fujita; K Sakaguchi; Y Shiratori
Journal:  Br J Cancer       Date:  2007-10-09       Impact factor: 7.640

View more
  5 in total

1.  Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.

Authors:  D Aydin; A Bilici; S Kayahan; D Yavuzer; M Basar; M Aliustaoglu
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

2.  Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation.

Authors:  Neema Jamshidi; Maximilian Diehn; Markus Bredel; Michael D Kuo
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

3.  Ablation of Rassf2 induces bone defects and subsequent haematopoietic anomalies in mice.

Authors:  Hoogeun Song; Hyunsoo Kim; Kyunghee Lee; Da-Hye Lee; Tae-Shin Kim; Ji Yun Song; Dongjun Lee; Dongwook Choi; Chang-Yong Ko; Han-Sung Kim; Hong-In Shin; Juhyun Choi; Heedong Park; Chankyu Park; Daewon Jeong; Dae-Sik Lim
Journal:  EMBO J       Date:  2012-01-06       Impact factor: 11.598

4.  Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients.

Authors:  Deng Luo; Ting Ye; Tian-Qian Li; Peng Tang; Sha-Dong Min; Gong-Fang Zhao; Hua Huang; Jiang Chang; Yan Wang; Lin Lv; Ming-Liang Lu; Meng-Yao Zheng
Journal:  Exp Ther Med       Date:  2011-12-28       Impact factor: 2.447

5.  Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma.

Authors:  Diego F Calvisi; Matthias Evert; Frank Dombrowski
Journal:  Mol Biol Int       Date:  2012-04-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.